Active Pharmaceutical Ingredients (APIs) are the most critical and the most complex element to manufacture, source, and control.

Across the pharmaceutical industry, APIs are sourced from specialized manufacturers with the equipment, expertise, and regulatory framework required to handle these materials safely and consistently. Once produced and tested, APIs are supplied to pharmaceutical manufacturers, who then formulate, package, and distribute the final drug product.

Recent global supply disruptions have highlighted just how concentrated API manufacturing has become. A significant portion of generic pharmaceutical APIs are produced in a small number of countries, creating vulnerabilities related to availability, quality oversight, and logistics. These challenges have been felt acutely by pharmaceutical manufacturers.

At Agrisan, we are licensed to import and test active pharmaceutical ingredients, as well as, manufacture drug, veterinary health, and natural health products. This capability is supported by our purpose-built production facility, quality systems, and qualified personnel with experience working under Good Manufacturing Practices (GMPs). Our laboratory is equipped with the personnel, tools and systems that allow us to ensure safety, identity, strength, purity, and quality throughout the manufacturing process.

“Working with APIs requires more than access to raw materials. It requires discipline, documentation, and the ability to verify every step,” says Michael J MacFarland, B.Sc.(Agr.), ASQ CQA, Quality Manager. “Our focus is on building processes that clients can trust, as regulations and supply conditions evolve.”

While sourcing APIs can be challenging particularly as regulatory requirements increase, our purchasing scale, supplier relationships, and infrastructure allow us to navigate these constraints effectively. We do not sell APIs directly to consumers; instead, we support pharmaceutical manufacturers seeking a reliable partner capable of producing compliant drug products that include active ingredients.

As regulatory expectations continue to evolve, our approach remains consistent: invest in quality systems, maintain regulatory awareness, and design facilities and processes that are built for long-term compliance.